Aptose Biosciences Inc (APS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 02-2014 | 11-2013 | 08-2013 | 05-2013 | 02-2013 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 4 | 4 | 4 | 10 | 9 |
| Accounts payable and accrued liabilities | 96 | -447 | -46 | 488 | -116 |
| Other Working Capital | -157 | 307 | 39 | 267 | -41 |
| Other Operating Activity | -1,913 | -1,261 | -882 | -1,613 | -1,095 |
| Operating Cash Flow | $-1,969 | $-1,398 | $-885 | $-849 | $-1,243 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4 | -3 | N/A | N/A | N/A |
| Other Investing Activity | 12 | 0 | 1 | 4 | 9 |
| Investing Cash Flow | $7 | $-3 | $1 | $4 | $9 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 0 | N/A | 871 | 6 | 0 |
| Debt Issued | 0 | 706 | N/A | N/A | N/A |
| Common Stock Issued | 6,540 | 0 | 0 | -40 | 0 |
| Other Financing Activity | 358 | 1,767 | -38 | -1 | 0 |
| Financing Cash Flow | $6,898 | $2,473 | $833 | $-35 | $0 |
| Beginning Cash Position | 1,562 | 564 | 619 | 1,516 | 2,751 |
| End Cash Position | 6,498 | 1,637 | 568 | 634 | 1,516 |
| Net Cash Flow | $4,936 | $1,073 | $-51 | $-880 | $-1,235 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,969 | -1,398 | -885 | -849 | -1,243 |
| Capital Expenditure | -4 | -3 | N/A | N/A | N/A |
| Free Cash Flow | -1,974 | -1,401 | -885 | -849 | -1,243 |